ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mirdametinib

Also written as “Mirdametinib”, “PD-0325901” and “Mirdametinib (MEK Inhibitor)”.

Its studies are mostly in Neurofibroma, Plexiform · Melanoma · Carcinoma, Non-Small-Cell Lung, led by 3 companies.

Drug pageMirdametinib: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Apr 12, 20199 company-led studies, 4 open or runningNext primary completion: Nov 27, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germanyits history only64 open or runningphase 2since Apr 12, 2019Apr 12, 2019Nov 27, 2026phase 1 · NCT06997276
Pfizer20 open or runningphase 2since Sep 2, 2005Sep 2, 2005none ahead
BeOne Medicinesits history only10 open or runningphase 1since Apr 3, 2019Apr 3, 2019none ahead

Also a collaborator on its studies: SpringWorks Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 2, 2005First studies: 2 phase 2 studiesFirst studyNCT00147550, NCT00174369
  2. Dec 9, 2019Named mirdametinibINNProposed as its International Nonproprietary Name in WHO's List 122 · before, PD-0325901

TargetBeta

“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
cobimetinibruleHoffmann-La Rochephase 338
pimasertibruleMerck KGaA, Darmstadt, Germanyphase 213
polfurmetinibPfizerphase 13

Studies

All 2 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00174369Carcinoma, Non-Small-Cell Lung · United States2TerminatedJun 200734
NCT00147550Melanoma · United States2TerminatedMay 200779

How it is read

Names in the registry

  • “Mirdametinib”, 2 entries
  • “PD-0325901”, 2 entries
  • “Mirdametinib (MEK Inhibitor)”, 1 entry
  • “Mirdametinib (PD-0325901) oral capsule or dispersible tablet”, 1 entry
  • “Mirdametinib 2mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.